EUROPEAN ADDENDUM TO THE CLINICAL TRIAL COLLABORATION AGREEMENT BETWEEN MEDTRONIC AND ARCACollaboration Agreement • March 21st, 2017 • ARCA Biopharma, Inc. • In vitro & in vivo diagnostic substances
This addendum (“Addendum”) is made as of September 14, 2016 and is to the Clinical Trial Collaboration Agreement (the “Collaboration Agreement”) made and entered into as of April 18, 2013 between ARCA biopharma, Inc., a Delaware corporation (hereinafter “ARCA”) and Medtronic, Inc., a Minnesota corporation (hereinafter “Medtronic”), as amended by the Second Amendment to the Collaboration Agreement entered as of August 28, 2014. This Addendum is for the purpose of supply and distribution of Medtronic devices and CareLink services within Europe under the Collaboration Agreement.
